Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
Steady-state pharmacokinetics of oral fleroxacin were studied in six males who had skin or skin structure infections and who were receiving 400 mg of fleroxacin once a day. Blood samples (n = 10) and total urine output were collected during a 24-h dosing interval. Fleroxacin concentrations in serum and urine were determined by high-performance liquid chromatography. The maximum concentration in serum and the time to achieve that maximum were 6.2 +/- 2.2 micrograms/ml and 0.94 +/- 0.62 h, respectively. The absorption half-life, alpha half-life, beta half-life, apparent steady-state volume of distribution, apparent total body clearance, and renal clearance were 0.56 +/- 0.37 h, 0.78 +/- 0.51 h, 10.56 +/- 1.40 h, 0.85 +/- 0.31 liters/kg, 129.2 +/- 19.6 ml/min, and 53.3 +/- 16.7 ml/min, respectively. Fleroxacin disposition in this patient population was similar to that in noninfected volunteers with normal renal function.
Heim-Duthoy
K
K
Department of Medicine, Hennepin County Medical Center, College of Pharmacy, University of Minnesota, Minneapolis 55415.
Peltier
G
G
Awni
W
W
D000328:Adult; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016576:Fleroxacin; D006207:Half-Life; D006801:Humans; D008297:Male; D012874:Skin Diseases, Infectious / Q000188:drug therapy / Q000378:metabolism*
D002939:Ciprofloxacin; D016576:Fleroxacin